
Selank
Tuftsin-based peptide studied for stress responses, calming signals, and immune activity.
For Research Use Only
Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.
The lower price is applied automatically once your cart holds 5 or more of this vial.
Bacteriostatic water included
About this peptide
Selank is a synthetic analogue of an active fragment of tuftsin, an immune-system peptide. It is studied primarily for its anxiolytic (anxiety-reducing) effects, with research examining its ability to modulate brain chemistry and support stress management without producing sedation. Researchers also investigate Selank for cognitive support and mood regulation, with published studies exploring its effects on memory consolidation, mental stability, and emotional balance in laboratory models.
Why researchers reach for Selank
Anxiolytic-like data
Referenced in rodent anxiety and stress-response models.
Enkephalin stabilization
Reduces breakdown of endogenous enkephalins in vitro.
Immunomodulation
Alters cytokine expression in preclinical work.
Key features
- ≥99% HPLC purity
- Tuftsin-derived heptapeptide
- Mass-spec verified
- Cold-chain dispatch
How it works
GABA system
Modulates GABA receptor expression in rodent brain regions.
Enkephalin pathway
Inhibits enkephalin-degrading enzymes.
Cytokine signaling
Adjusts IL-6 and interferon expression in animal models.
Research dosage guidelines
Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.
| Range | Reported dose | Note |
|---|---|---|
| Typical reconstitution | 2 mL bacteriostatic water | Yields 5 mg/mL (5000 mcg/mL) |
| Reported research range | 250–750 mcg/day | Reference only |
Tracking this compound? Registered researchers can log active Selank protocols in their private Research Log.
Timing in research protocols
Intranasal, two to three times across waking hours, over multi-week courses.
- Approved Russian product labelling reports 92.8% intranasal bioavailability, plasma appearance within 30 seconds and clearance in roughly 5 minutes.
- That very short half-life is why trials (Zozulya 2008; Medvedev 2015) use repeated daily intranasal dosing rather than a single dose.
- Reported frequency in the primary literature is two to three times daily, spread across waking hours.
- No morning-versus-evening rationale is established beyond covering the waking day; courses run for weeks.
Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.
Technical specifications
- Sequence
- Thr-Lys-Pro-Arg-Pro-Gly-Pro
- Molecular weight
- 751.9 g/mol
- Purity
- ≥99% (HPLC)
- Form
- Lyophilized powder
- Vial size
- 10 mg
- Storage (lyophilised vial)
- Cool, dry and protected from light
- Storage (after reconstitution)
- 2–8°C
Published research
Peer-reviewed literature on Selank. Links open in a new tab.
Research use notice
Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.
